Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01340599 | Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery | terminated | Phase 2 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00064311 | Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 8, 2012 |
| clinicaltrials |
| NCT01132599 | Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer | withdrawn | Phase 2 | 0 | Cancer Research UKOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00242918 | Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer | completed | Phase 2 | 29 | Benaroya Research InstituteOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00736164 | Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Feb 6, 2012 | clinicaltrials |
| NCT00147680 | Uterine Papillary Serous Cancer (UPSC) Trial | completed | Phase 2 | 30 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Feb 2, 2012 | clinicaltrials |
| NCT01132404 | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 | terminated | Phase 1 / Phase 2 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 31, 2012 | clinicaltrials |
| NCT00607607 | A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer | completed | Phase 2 | 44 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00126165 | Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 72 | Alberta Health servicesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00020696 | Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 4 | Jan 10, 2012 | clinicaltrials |
| NCT00116779 | A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer | completed | Phase 2 | 127 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 19, 2011 | clinicaltrials |
| NCT00569257 | Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors | completed | Phase 2 | 85 | AEterna ZentarisINDUSTRY | 2 | Dec 13, 2011 | clinicaltrials |
| NCT01487902 | The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer | unknown | Phase 2 | 90 | Asan Medical CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00550810 | Sutent Maintenance After Response to Taxotere(SMART) | unknown | Phase 2 | 30 | Alberta Health servicesOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT01487226 | Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer | unknown | Phase 2 | 69 | Korean Gynecologic Oncology GroupOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT01153113 | Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines | withdrawn | Phase 1 / Phase 2 | 0 | University of FloridaOTHER | 0 | Dec 2, 2011 | clinicaltrials |
| NCT00003887 | Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients(MIMOSA) | terminated | Phase 2 / Phase 3 | 888 | Menarini GroupINDUSTRY | 9 | Nov 24, 2011 | clinicaltrials |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse | terminated | Phase 2 | 9 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 10, 2011 | clinicaltrials |
| NCT00973882 | Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers | completed | Phase 2 | 60 | Centre Leon BerardOTHER | 1 | Nov 3, 2011 | clinicaltrials |
| NCT00005857 | Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | completed | Phase 2 | — | City of Hope Medical CenterOTHER | 1 | Oct 20, 2011 | clinicaltrials |
| NCT00036075 | Study Using CP-461 to Treat Advanced Prostate Cancer | completed | Phase 2 | 25 | Astellas Pharma IncINDUSTRY | 1 | Oct 17, 2011 | clinicaltrials |
| NCT00466986 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 40 | Southeastern Gynecologic OncologyOTHER | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00129025 | Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 35 | Alberta Health servicesOTHER | 1 | Oct 10, 2011 | clinicaltrials |
| NCT00741364 | Vitamin D Effects on Prostate Pathology(DProstate) | unknown | Phase 2 | 90 | University of TorontoOTHER | 1 | Sep 30, 2011 | clinicaltrials |
| NCT00452387 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 22 | Accelerated Community Oncology Research NetworkOTHER | 1 | Sep 16, 2011 | clinicaltrials |
| NCT01409876 | HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy | unknown | Phase 2 | 100 | University Hospital ErlangenOTHER | 1 | Aug 4, 2011 | clinicaltrials |
| NCT00429559 | Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma | completed | Phase 1 / Phase 2 | 31 | Hellenic Oncology Research GroupOTHER | 1 | Jul 22, 2011 | clinicaltrials |
| NCT00286793 | Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC | completed | Phase 1 / Phase 2 | 76 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00593580 | Bone Health in Gynecologic Cancers-does FOSAVANCE Help?(FOSAVANCE) | completed | Phase 2 | 60 | British Columbia Cancer AgencyOTHER | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00148772 | Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy | completed | Phase 2 | 29 | Endeavor HealthOTHER | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00050596 | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | — | Bristol-Myers SquibbINDUSTRY | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00651417 | Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue | unknown | Phase 2 | 101 | Arizona Oncology ServicesOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT01225471 | Novel Peptide Vaccination for Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 30 | Iwate Medical UniversityOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT00004177 | Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer | completed | Phase 1 / Phase 2 | 15 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00134654 | Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 16, 2011 | clinicaltrials |
| NCT00489359 | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 86 | Eli Lilly and CompanyINDUSTRY | 5 | Jun 16, 2011 | clinicaltrials |
| NCT00268593 | Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer | completed | Phase 2 | 48 | Progen PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT00069888 | A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy | completed | Phase 2 | 83 | SanofiINDUSTRY | 1 | Jun 8, 2011 | clinicaltrials |
| NCT00292955 | Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma | unknown | Phase 2 | 30 | University of VirginiaOTHER | 1 | May 30, 2011 | clinicaltrials |
| NCT00117312 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 37 | Ferring PharmaceuticalsINDUSTRY | 1 | May 23, 2011 | clinicaltrials |
| NCT00117949 | Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486 | completed | Phase 2 | 82 | Ferring PharmaceuticalsINDUSTRY | 1 | May 23, 2011 | clinicaltrials |
| NCT00750386 | Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | completed | Phase 1 / Phase 2 | 50 | Hellenic Oncology Research GroupOTHER | 1 | May 23, 2011 | clinicaltrials |
| NCT00215657 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 131 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
| NCT00245466 | Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients | terminated | Phase 2 | 88 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
| NCT00554086 | Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.(CHICS) | completed | Phase 2 | 65 | Canadian Urology Research ConsortiumOTHER | 1 | May 16, 2011 | clinicaltrials |
| NCT00627354 | Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 90 | Groupe D'Etude des Tumeurs Uro-GenitalesOTHER | 1 | May 16, 2011 | clinicaltrials |
| NCT00002506 | Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer | completed | Phase 2 | — | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00193271 | Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer | completed | Phase 2 | 30 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00003160 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | unknown | Phase 2 | 100 | TheradexINDUSTRY | 1 | Apr 20, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2012source: clinicaltrials